www.bioss.com.cn
400-901-9800
sales@bioss.com.cn
techsupport@bioss.com.cn
Rabbit  Anti-HGFA Inhibitor 2/Gold
Cat. Number:
bs-10062R-Gold
Quantity size:
100ul   15nm
Concentration:
0.4mg/ml  Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Tissue damage, such as hepatic and renal injury, initiates hepatocyte growth factor activator (HGFAC)-mediated limited proteolytic activation of the inactive single-chain precursor form of HGF. Initially, HGFAC is produced as a precursor protein, which is activated by limited proteolysis and is neutralized by specific inhibitors known as HGF activator inhibitors, designated HAIs. HAIs belong to the Kunitz-type serine protease inhibitor family. HAIs target HGF activator and are involved in the regulation of proteolytic activation of HGF in injured tissues. Human HAI-1 transcript is expressed in various human tissues, such as adult placenta, kidney, pancreas, prostate and small intestine, and fetal kidney and lung. It translates into a 478 amino acid protein. The human HAI-2 gene maps to chromosome 19q13.1 and encodes a 252 amino acid protein, also designated human placental bikunin or kop (Kunitz domain containing protein over-expressed in pancreatic cancer). HAI-1 and HAI-2 are produced in membrane-associated forms, which are secreted as active, proteolytically truncated proteins.
Also known as:
Bikunin, placental; DIAR3; HAI-2; HAI2; Hepatocyte growth factor activator inhibitor type 2; Kop; Kunitz type protease inhibitor 2; Kunitz-type protease inhibitor 2; Kunitz-type serine protease inhibitor; PB; Placental bikunin; HGFA Inhibitor2; HGFA Inhibitor-2; Serine peptidase inhibitor Kunitz type 2; Serine protease inhibitor, Kunitz type, 2; SPINT2; SPIT2_HUMAN.
Specificity:
Rabbit Polyclonal IgG, affinity purified by Protein A.
Reacts with: (predicted: )
Immunogen: KLH conjugated synthetic peptide derived from human SPINT2/HAI2/HGFA Inhibitor 2.
Predicted Molecular Weight: 28kDa.
Storage:
0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles.
Application:

Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.